One of the most widely used treatments for non-small cell lung cancer (NSCLC) is the combination of paclitaxel-cisplatin. These drugs may contribute to taste alterations like dysgeusia. Which alters the feeding of cancer patients, contributing to the anorexia, weight loss and malnutrition, which leads to a prognostic impact in a lower patient response to chemotherapy, radiotherapy and surgical treatment as well as increased toxic effects, impacting treatment discontinuation and therefore, morbidity and survival of patients. The objective of this study is to describe the threshold of perception and recognition of basic tastes in patients with NSCLC before treatment with platin and paclitaxel-based chemotherapy and after the second cycle, and analyze the effect in the developement of dysgeusia, as well as the association between these and the nutritional status and quality of life.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Dysgeusia (UMAMI Perception)
Timeframe: Change from Baseline in threshold of perception at 6 weeks
Dysgeusia (UMAMI Recognition)
Timeframe: Change from Baseline in threshold of perception at 6 weeks
Dysgeusia (SWEET Perception)
Timeframe: Change from Baseline in threshold of perception at 6 weeks
Dysgeusia (SWEET Recognition)
Timeframe: Change from Baseline in threshold of perception at 6 weeks
Dysgeusia (BITTER Perception)
Timeframe: Change from Baseline in threshold of perception at 6 weeks
Dysgeusia (BITTER Recognition)
Timeframe: Change from Baseline in threshold of perception at 6 weeks
Dysgeusia (UMAMI Dilutions Dichotomized)
Timeframe: pre - post chemotherapy (6 weeks)
Dysgeusia (SWEET Dilutions Dichotomized)
Timeframe: pre - post chemotherapy (6 weeks)
Dysgeusia (BITTER Dilutions Dichotomized)
Timeframe: pre - post chemotherapy (6 weeks)